Gene-directed enzyme prodrug therapy is a form of targeted cancer therapy, in which an enzyme is used to convert a non-toxic prodrug to a cytotoxin within the tumor. Horseradish peroxidase (HRP) is able to convert the indole prodrugs indole-3-acetic acid (IAA) and the halogenated derivative 5-bromo-IAA (5Br-IAA) to toxic agents able to induce cell kill in vitro. This study characterized HRP-directed gene therapy in vivo. Human nasopharyngeal squamous cell carcinoma cells, FaDu, stably expressing HRP were grown as xenografts in SCID mice. Pharmacokinetic analysis of IAA and 5Br-IAA showed satisfactory drug profiles, and millimolar concentrations could be achieved in tumor tissue at non-toxic doses. HRP-expressing tumors showed a modest growth delay when treated with IAA compared with drug-vehicle controls. Treatment response could not be improved using different drug scheduling or drug vehicle, nor by combining HRP-directed gene therapy with fractionated radiotherapy.
Introduction
Gene-directed enzyme prodrug therapy (GDEPT) is designed as a form of targeted cancer therapy, in which an enzyme-encoding gene is delivered to convert a nontoxic prodrug to a cytotoxin specifically within the tumor. 1, 2 To this end, the horseradish peroxidase (HRP) has been used to convert the indole prodrug indole-3-acetic acid (IAA), and several of its analogs, to toxic agents to induce cell kill in vitro. [3] [4] [5] IAA is a plant auxin involved in the regulation of plant cellular growth, division, and differentiation, as well as a natural metabolite in mammals of the amino-acid tryptophan by monoamine oxidase. 6 The cytotoxicity of 10 IAA analogs after activation by HRP-expressing cells has been studied, and IAA, 1-methyl-IAA, and 5-bromo-IAA (5Br-IAA) represented the most promising candidates for HRP-directed gene therapy. 4 Specifically, 5Br-IAA was found to be highly potent in air and in anoxia. 4 The HRP/IAA system is capable of reducing glutathione levels, 7 and inducing DNA strand breaks. 8, 9 IAA was able to selectively sensitize HRP-expressing human bladder carcinoma cells to the effects of radiation. 10 Importantly, IAA was able to increase sensitivity under anoxic conditions, in which radical fixation is less likely to occur.
The HRP/IAA combination was shown to retain its activity under the tumor-simulated conditions seen in three-dimensional tumor cell spheroids. 11 In particular, 5Br-IAA showed specificity against larger spheroids, which contain significant regions of hypoxia. Although monolayers and spheroids can be manipulated to approximate the conditions seen in solid tumors, they are far less complex than the neoplastic conditions seen in patients. Animal models remain the most realistic experimental approximation to the clinical situation. It is, therefore, necessary for novel therapeutics to be evaluated in vivo.
This study set out to characterize human tumor xenografts stably expressing HRP, in vivo indole distribution and toxicity, and efficacy of HRP-directed gene therapy in an animal model.
Materials and methods

Animal studies
Animal experiments were carried out in a specific pathogenfree animal unit using female SCID (C.B-17crCru-scid/scid homozygotes) mice bred in the Gray Cancer Institute. Procedures were performed with approved protocols in accordance with the UK Animals (Scientific Procedures) Act 1986, and the local ethics committee. All experiments involving genetically modified cells grown as tumors were carried out following Health and Safety Executive guidelines and according to the institutional code of practice (Gray Cancer Institute) using protocols approved by the Health and Safety Executive. Mice bearing genetically modified tumors were handled double gloved in a class II laminar flow hood, and housed in cages fitted with HEPA filters within internally ventilated racking. Animals were kept on a 12/12 h day/night cycle with food and water available ad libitum.
Cell culture
Human nasopharyngeal squamous cell carcinoma cells, FaDu, were obtained from the American Type Culture Collection (Manassa, VA) and maintained in Dulbecco's modified Eagle's medium (Life Technologies, Paisley, UK) supplemented with 10% fetal calf serum (Sigma, Poole, UK) and 2 mM L-glutamine (Life Technologies). Cells were kept in a humidified incubator at 37 1C and 5% CO 2 /air. FaDu cells stably transfected with either the HRP gene, clone HRP8, or the marker green fluorescent protein, clone GFP1, were generated earlier 11 and were used throughout the experiments.
Tumor implantation
FaDu cells (parental GFP1 and HRP8) from in vitro cell culture were implanted subcutaneously at 10 6 /mouse on the backs of female SCID mice under general anesthesia (metofane, C-vet Ltd, Bury St Edmunds, Suffolk, UK) to form xenografts. Tumor measurements were made daily in three dimensions using callipers, and volume was calculated using the following formula: V ¼ (a*b*c*p)/6.
Transgene expression HRP activity was assessed using a modified version of the 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) assay as described earlier. 3 Samples from tumor tissue were suspended in 0.5% hexadecyltrimethylammonium bromide, lysed by freeze/thaw in liquid nitrogen/37 1C, cleared by centrifugation, incubated at 60 1C for 2 h, and the supernatant was collected and stored at À20 1C until analysis.
GFP was visualized by fluorescence microscopy using frozen, unfixed 10 mm thick tumor sections. 12 
Assessment of vascular density
Frozen tumor sections were stained for CD34 to detect blood vessels following manufacturer's instructions (rat anti-mouse CD34, 1:200, MCA1825, Serotec, Kidlington, UK). Vessel density was quantified using a Chalkley eyepiece graticule (Graticules Ltd, Tonbridge, Kent, UK) essentially as described earlier. 13 Briefly, under Â 100 magnification, the field of view was moved randomly over the section, and the number of dots in contact with positively staining blood vessels counted. This was repeated at least 20 times per section area. The vascular index was calculated by averaging the scores for each section. Three sections were cut at three levels through the tumor (approximately 2-3 mm apart), five tumors per group, and the results pooled.
Assessment of hypoxic fraction
Pimonidazole hydrochloride in phosphate-buffered saline was injected intraperitoneally (i.p.) to mice at 60 mg kg -1 . Animals were killed 90 min later, tumors were excised and frozen in OCT, 5 mm sections were cut using a Bright cryostat, and collected on poly-L-lysine-coated glass slides. Pimonidazole staining was carried out using an UltraVision Mouse Tissue Detection System (Stratech Scientific, Newmarket, Suffolk, UK), following the manufacturers instructions, and an anti-pimonidazole IGg1 antibody (Natural Pharmacia Intl Inc, Burlington, MA) diluted 1:100 in TBS with protein block (Dako, Ely, Cambridgeshire, UK). Staining was identified using the diaminobenzidine chromophore, and slides were counterstained with hematoxylin. Sections from at least three levels through the tumor were analyzed using Image J software (public domain Java image processing program). Regions of positive staining were manually highlighted, and pixel area expressed as a percentage of total section area.
Maximum-tolerated dose of indoles
The maximum-tolerated dose was determined to prevent potential drug induced side effects during dosing. Prodrugs were administered i.p. to non-tumor bearing female SCID mice at a range of doses for 7 days, and animal health monitored during this period and for 1 month subsequently.
Pharmacokinetics
Female SCID mice bearing parental FaDu tumors received a single dose of IAA in 10% ethanol or 5% DMSO, or 5Br-IAA in 10% ethanol i.p. At specified times after administration, animals were killed and blood and tissues removed. Whole blood was collected in lithium-heparin tubes (Sarstedt, Beaumont Leys, Leicester, UK), centrifuged, and plasma removed to tubes containing ascorbate. Levels of IAA and 5Br-IAA were determined by HPLC similar to what has been described for 5-fluoro-IAA.
14 Briefly, tissues were weighed, homogenized in nine volumes of 0.1% ascorbate solution, and transferred to microfuge tubes. Protein was precipitated by the addition of an equal volume of acetonitrile to the sample, supernatant was removed to sample vials, and loaded into an autosampler (Waters 717, UK) attached to a HiChrom RPB 100 Â 3.2 mm reverse phase column. Eluent A was composed of 10% acetonitrile, 20 mM ammonium acetate at pH 5.1, and eluent B consisted of 75% acetonitrile/water. The column was run with a 0-50% gradient of B over an 8-min period with a flow rate of 1 ml min -1 and a re-equilibration time of 5 min. Detection was with a Waters 996 diode array detector at 260 nm. To check the recovery of IAA from proteinprecipitated samples, control plasma, or water, was spiked with 5 mM IAA. Area under the drug concentration curve (AUC) was calculated using Origin graph package software.
Ex vivo clonogenic assay
Animals bearing GFP1 or HRP8 tumors received a single i.p. administration of 200 mg kg -1 prodrug in 10% ethanol when tumors reached approximately 6 mm in diameter; 24 h later, tumors were excised, weighed, and disintegrated as described earlier. 15 Viable cells were plated with feeder cells (V79 cells (American Type Culture Collection, Manassa, VA) exposed to 250 Gray (Gy) 60 Co) and colonies allowed to form over 10 days in a CO 2 incubator.
Tumor growth delay
Tumor-bearing animals were treated with prodrug by i.p. administration when tumors reached 5-6 mm in diameter.
Growth delay experiments with a 7-day dosing period were performed with both prodrugs. Tumor size was monitored by serial calliper measurements and animal weight was recorded throughout. Animals were killed when tumors reached 600-800 mm 3 .
Radiation treatment
Local tumor irradiation was carried out without anesthetic using specially designed lead jigs, exposing only the tumor-bearing rear dorsum to a horizontal X-ray beam. 16 For this reason, tumors were implanted on the rear dorsum. Six mice were simultaneously irradiated with 240 kV X-rays to give a total dose of 2 Gy per tumor (divided into two doses of 1 Gy to each side of the tumor) per day for 5 days to give a total dose of 10 Gy. Radiation was administered 20 min after prodrug injection. Prodrug administration was continued daily for a total of 21 days.
Statistical analysis
The mean levels were compared between groups using ANOVA. Where significant differences between groups were identified, these were further explored using Students t-test. Tumor growth data were fitted to a multivariate model (MANOVA) with repeated measures, and differences between treated and control groups were tested for significance using an approximate F-test. In all cases, differences between groups were described as significant if the probability corresponding to the appropriate statistic was o0.05.
Results
Characterization of FaDu tumors
Parental FaDu, GFP1, and HRP8 cells, implanted subcutaneously on the backs of female SCID mice, formed solid tumors with a take rate of 100%. The parental and HRP8 tumors grew at the same rate, with tumor doubling times of approximately 2 and 3 days, respectively ( Figure 1a) . The growth rate of GFP1 tumors was noticeably slower (doubling time of 8 days) in these immunodeficient animals. This is in contrast to growth in vitro in which all three clones grew at similar rates. 11 The expression of transgenes in tumors was preserved in vivo. GFP1 tumors showed diffuse, often punctate expression of GFP throughout the tumor. HRP8 tumors showed greater enzyme activity by TMB assay than tumors grown from either parental or GFP1 cells (Figure 1b ).
Tumors were analyzed histologically to determine whether transgene expression changed tumor characteristics. Vascular density of GFP1 tumors was significantly lower than that of parental or HRP8 tumors (Figure 1c ). Pimonidazole staining, indicating areas of hypoxia, was present throughout the tumors and showed no significant difference between the three tumor lines. Parental tumors showed 7.66% ± 1.3% area positively stained for pimonidazole, GFP1 tumors 8.18%±3.6, and HRP8 tumors 
Characterization of prodrugs
The weights of animals receiving IAA at 200 mg kg -1 or 5Br-IAA 200 mg kg -1 did not significantly decrease during or after treatment (o5% change from original weight). Animals appeared to be in good health, with no diarrhea, piloerection, or hunching behavior. However, after 4 days administration of IAA at 300 mg kg -1 , animals displayed myotonia (decreased muscle tone and decreased reaction time), and seemed to be hypothermic. Animals were killed at this time.
Pharmacokinetic parameters for IAA and 5Br-IAA are detailed in Table 1 . Pharmacokinetic studies showed that administration of a single dose of 250 mg kg -1 IAA in ethanol resulted in a profile resembling a first-order process (Figure 2a) . Plasma, liver, and skeletal muscle concentrations peaked 10 min after administration, remained relatively constant for a short absorption phase, with a peak plasma concentration of 1.1 mM (±0.1) at 20 min. At the 240 min sampling time, there was a large variation in IAA concentrations between animals. The effect of solvent was determined using DMSO in place of ethanol. The pharmacokinetic profile of IAA in DMSO (Figure 2b ) was markedly different from that seen when ethanol was used. With the exception of the liver, all tissues showed a short absorption phase. In the tumor, this lasted 90 min. Plasma concentrations reached 2.5 mM (±0.05), and the peak tumor concentration was 2.5 mM ( ± 0.3), which is greater than the maximal concentration achieved using ethanol. The tumor AUC 0-240 for IAA in DMSO was more than twice that seen when IAA was administered in ethanol. The plasma t 1/2 was also extended, and data more closely fitted an exponential decrease in tissue concentrations.
The halogenated prodrug 5Br-IAA was administered in 10% ethanol at 150 mg kg -1 ( Figure 2c ). As for IAA, concentrations were initially highest in the plasma and liver. However, whereas elimination of IAA from the blood and the liver was at approximately the same rate, 5Br-IAA was eliminated from the liver at a faster rate than from the plasma. At 240 min, tumor levels were greater than those in the liver. Tumors showed an absorption period of approximately 1 h to give a maximal concentration of 1.0 mM (±0.01), before slowly being eliminated. Skeletal muscle again showed the lowest prodrug concentrations. There was less inter-animal variation after administration of 5Br-IAA in ethanol than IAA in ethanol.
Ex vivo clonogenic analysis of HRP GDEPT efficacy
Ex vivo clonogenic assays indicated that a dose of 200 mg kg -1 IAA gave a 60% reduction in HRP8 cell survival compared with vehicle-treated controls, whereas 5Br-IAA led to a 45% reduction in survival. Administration of both prodrugs to animals bearing GFP1 tumors did not decrease tumor cell survival. However, the plating efficiency in all experiments was extremely low (o0.001%), and the use of a soft agar assay 17 
did not improve the ability of FaDu cells to form colonies (results not shown).
Tumor growth delay to analyze HRP GDEPT efficacy Administration of IAA at 200 mg kg -1 for 7 days gave a small growth delay of approximately 5 days in HRP8 tumors compared with vehicle only (P ¼ 0.018; Figure 3A) . There was no effect of vehicle (10% ethanol) on tumor growth, and IAA did not have a significant effect on the growth of GFP1 tumors. Administration of 5Br-IAA had no significant effect on growth of HRP8 or GFP1 tumors ( Figure 3B ). However, after three 5Br-IAA administrations, one HRP8 animal was found dead, and two GFP1 animals were found dead after four administrations. It would seem that this dose of 5Br-IAA, although without effect in non-tumor-bearing animals, is toxic to those with tumors.
To achieve a greater exposure of drug and reduce drug toxicity, administration of 5Br-IAA was attempted twice daily (b.i.d.) at 50-150 mg kg -1 in 10% ethanol ( Figure 3C ). This seemed to slow growth in HRP8 tumors, especially at the lower dose of 50 mg kg -1 . However, there were adverse effects, and all animals at this dose had to have treatment stopped after 4 days because of unacceptable losses of body weight (10%), although in most cases, this recovered on cessation of treatment (results not shown). This loss of body weight was also seen to a lesser degree in vehicle-treated animals. Animals bearing GFP1 tumors also displayed decreased body weights with b.i.d. dosing, although to a far lesser degree than HRP8 tumor-bearing animals. GFP1 tumor growth seemed slightly reduced in 5Br-IAA-treated groups.
Owing to the differences in pharmacokinetic behavior, growth delay experiments were repeated to directly compare the effect of vehicle on prodrug activity using either 10% ethanol or 5% DMSO. No significant differences were detected between treatment with vehicle and treatment with either IAA or 5Br-IAA, in either ethanol or DMSO, for either GFP1 or HRP8 tumors ( Figure 3D ). Treatment of FaDu cells in vitro with IAA in either 10% ethanol or 5% DMSO resulted in virtually identical survival curves (results not shown).
Combination of HRP GDEPT with radiotherapy
Radiation alone resulted in approximately 25 days of growth delay in both parental and HRP8 tumors ( Figure 4A ). Tumors remained at the initial treatment size for about 1 week after the cessation of radiation treatment, then increased, but with a slower growth rate than tumors not exposed to radiation. FaDu parental tumors served as controls rather than GFP1 tumors, as GFP tumors had a significantly different tumor growth pattern without treatment (Figure 1a) . Prodrug treatment seemed to slow growth slightly in parental tumors, although this was not significant. HRP8 tumors treated with indoles (IAA and 5Br-IAA) for 21 days showed a tendency to decreased tumor volume compared with vehicle-treated controls, however this was not significant. Addition of either of the indoles to radiation treatment did not further enhance the effectiveness of this therapy ( Figure 4A ).
To determine whether HRP-producing cells were selectively killed by prodrug treatment, enzyme activity in treated tumors was assessed. With the exception of vehicle controls, there was a tendency for enzyme activity to be greater in HRP8 tumors than in parental, although this was not significant for any of the treatment groups ( Figure 4B ). There was no difference in the amount of necrosis between treatments in the HRP8 tumors (data not shown).
Discussion
This study reports the characterization of HRP-expressing human tumor cells and indole compounds in an animal model, and the subsequent attempt to show a therapeutic effect for HRP-directed gene therapy in vivo. Despite an initial modest, yet promising, tumor growth delay, this could not be improved using different drug scheduling or drug vehicle, nor by combining HRPdirected gene therapy with fractionated radiotherapy. First, the prodrug concentration at the site may not have reached therapeutic levels. It was not possible to increase the dose of 5Br-IAA administered using fractionated dosing schedules, because of weight loss and nonspecific toxicities. It may be possible to increase the tumor exposure to prodrugs, and thus increase the potential cell kill, by modification of prodrugs. Several other indoles have earlier shown promise in in vitro toxicity assays in combination with HRP. 4 Second, the HRP gene expression, and hence activity, may have been suboptimal. In vitro enzyme activity was lower in transiently transfected FaDu cells (0.008 ± 0.2 U mg -1 protein, unpublished data) than stable transfectants 18 (HRP8: 0.08±0.003 U mg -1 protein). Yet, in vitro effectiveness of the HRP/IAA system in stable transfectants 11, 18 was less than in transient transfectants of the same cell line. 4 Enzyme activity per cell may be more important than enzyme activity per population of cells. In vivo, stably transfected FaDu grown as xenografts showed high TMB activity (0.24 U mg -1 protein, Figure 1 ), indicating sufficient enzyme activity for prodrug activation. It is important to note that different tumors have been shown to have varying amounts of peroxidase activity, 19 which may be related to the presence of myeloperoxidase activity in neutrophils and other leukocytes. 20 Myeloperoxidase activity cannot be distinguished from HRP activity using the TMB assay.
Stably transfected cell lines were chosen for this in vivo study because our preliminary data had indicated low efficiency of HRP gene transfer in vivo. Using a mouse carcinoma CaNT tumor model, the HRP gene was transferred in vivo using electroporation and/or cationiclipid-assisted DNA transfer, but only minimal HRP activity by TMB assay (0.07 U mg -1 protein, unpublished data) was shown, which was not significantly different from controls (own unpublished data).
Targeting the HRP protein to the nucleus may improve effectiveness, as the main cytotoxic target of activated indoles is contained within the cell nucleus. However, own pilot data showed that HRP GDEPT activity in vitro was not improved by using nuclear localization sequences (Dachs, unpublished) . The growth rate of GFP1 tumors was markedly lower, showed reduced vascularity, but similar hypoxic fractions, compared with parental cells. GFP1 cells, when grown as spheroids, did not have any growth disadvantage compared with parental or HRP8 cells.
11 GFP and the modified enhanced green fluorescent protein have been reported to produce a strong T cell-mediated immune response, 21 which can lead to both growth delay and spontaneous regression of tumors. However, SCID mice are unable to mount an effective immune response, as they are hypogammaglobulinemic and lack both B and T cells, 22 and thus the immunogenicity of GFP was unlikely to account for the reduced tumor growth rate. Reduced GFP1 tumor growth rate was most likely because of the observed reduction in vascularity, but the molecular basis is unknown. Owing to the difference in growth kinetics between the GFP1 and parental/HRP tumors, parental tumors were used as controls in the combination therapy studies (Figure 4) .
In this study, a multiple dosing strategy of 300 mg kg -1 IAA seemed to have severe adverse effects, with animals appearing flaccid and cold. Adverse effects were also seen with 5Br-IAA at 200 mg kg -1 and at 50-150 mg kg -1 b.i.d. Myotonia and hypothermia were also seen in male albino 23 and male ddY mice 24 after a single administration of 300 mg kg -1 IAA. IAA has reportedly been given to patients and volunteers, with no major toxicities reported after administration of 3-10 g. 25, 26 However, no detailed patient or clinical data from these old trials are available.
Tumor levels of IAA remained above 0.5 mM for approximately 2 h when administered in ethanol, and 44 h when dissolved in DMSO. In vitro exposure of HRP8 cells to 0.5 mM IAA resulted in a 20% decrease in survival of monolayers and almost a 50% decrease in the clonogenicity of HRP8 cells grown as spheroids (both 300 and 700 mm diameter 11 ). Tumor concentrations of 5Br-IAA reached 1 mM for approximately 30 min, and remained above 0.5 mM for 4 h. This concentration was sufficient to decrease clonogenicity of HRP8 cells in 700 mm diameter spheroids to 20%. 11 In vitro in monolayers, 5-Br-IAA was found to be highly potent at concentrations at and below 1 mM in anoxia, and a 2-h incubation at this concentration produced over two logs of cell kill. 4 Levels in the liver were 41 mM for 90 min. After 4 h exposure of cells in vitro, concentrations of 5 mM and above resulted in non-specific toxicity of GFP1 cells, which may indicate a potential for liver damage.
Considering that 5Br-IAA was administered at a lower dose than IAA, it showed promising pharmacokinetics. Choice of solvent may be important, as DMSO seemed to increase the tumor exposure to IAA without increasing peak liver, plasma, or muscle concentrations. Use of 5Br-IAA with DMSO may provide a more lengthy exposure of tumor and increased tumor AUC, yet growth delay results were disappointing.
Comparison of the pharmacokinetic data for IAA with existing GDEPT prodrugs shows that IAA has a considerably shorter half-life (GCV, 2-3 h; 27 5-FC, 3-4 h; 28 CB1954, 1.4-2 h 29 ). This will require the activation of IAA in a more rapid manner than existing strategies. In transient transfectants, IAA can lead to cytotoxicity in 2 h, 3 and cytotoxicity in V79 cells incubated with purified HRP and IAA occurred after 1 h. 7 Combination of GDEPT treatment with radiation is likely to be important in clinical protocols, and has been used experimentally with HSV-tk/GCV, 30,31 CD/ 5-FC, 32, 33 and NADPH reductase/bioreductives, 34 with at least an additive effect on tumor response. HRP/IAA treatment in vitro showed significant radiosensitization at clinically relevant X-ray doses under both oxic and anoxic conditions. 10 Unfortunately, combination of the HRP GDEPT system with radiation in vivo failed to increase the growth delay seen with a fractionated radiotherapy schedule. In vitro, the interaction between the HRP/IAA combinations was present regardless of whether IAA was present before, during, or after irradiation; 10 therefore, it is unlikely that the tumor effect in vivo was effected by the scheduling.
A recent study reported the use of intra-tumoral injection of the HRP gene, under control of the human telomerase reverse transcriptase promoter, 5 into xenografts grown from laryngeal squamous cell carcinoma cells, followed by IAA administration with radiation. 35 Tumor growth delay data seemed similar to those reported in this study, but reported 'inhibition rates' indicated a more impressive HRP/IAA effect, but a far less efficient radiation effect, compared with this study. Reported differences may be due to differences in DNA constructs and delivery, or tumor models.
Promising in vitro data using either purified HRP, transiently, or stably HRP-transfected cancer cells, or three-dimensional tumor models, had led to the in vivo evaluation of HRP-directed gene therapy. This is the first study to document the pharmacokinetic behavior of IAA and 5Br-IAA, as well as the potency of the HRP/5Br-IAA combination in vivo. Disappointingly, data from this xenograft model have shown only minor therapeutic activity of the HRP/indole combinations.
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